Tuberculosis: Current Status, Diagnosis, Treatment and Development of Novel Vaccines
-
Published:2019-07-09
Issue:6
Volume:20
Page:446-458
-
ISSN:1389-2010
-
Container-title:Current Pharmaceutical Biotechnology
-
language:en
-
Short-container-title:CPB
Author:
Yadav Jyoti1, Verma Sonali1, Chaudhary Darshna2, Jaiwal Pawan K.2, Jaiwal Ranjana1
Affiliation:
1. Department of Zoology, M.D. University, Rohtak-124001, India 2. Centre for Biotechnology, M.D. University, Rohtak-124001, India
Abstract
Tuberculosis (TB) is an infectious disease that mainly affects the lungs and spreads to other organs of the body through the haematogenous route. It is one of the ten major causes of mortality worldwide. India has the highest incidence of new- and multidrug-resistant (MDR) - TB cases in the world. Bacille Calmette-Guerin (BCG) is the vaccine commonly available against TB. BCG does offer some protection against serious forms of TB in childhood but its protective effect wanes with age. Many new innovative strategies are being trailed for the development of effective and potent vaccines like mucosal- and epitope-based vaccines, which may replace BCG or boost BCG responses. The use of nanotechnology for diagnosis and treatment of TB is also in the pipeline along with many other vaccines, which are under clinical trials. Further, in-silico models were developed for finding new drug targets and designing drugs against Mycobacterium tuberculosis (Mtb). These models offer the benefit of computational experiments which are easy, inexpensive and give quick results. This review will focus on the available treatments and new approaches to develop potent vaccines for the treatment of TB.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Biotechnology
Reference122 articles.
1. Bloom BR. N Engl J Med, New Promise for vaccines against tuberculosis.,, 2018, 379,, 1672-1674,10.1056/ NEJMe1812483 2. . N Engl J Med, Global investments in Tuberculosis research and development: past, present and future. A policy paper prepared for the first WHO global ministerial conference on ending tuberculosis in the sustainable development era: A multisectoral response. Geneva: World Health Organization; 2017, Licence: CC BY-NC-SA 3.0 IGO. ,, , 379,, 1672-, 3. Singh SK, Kashyap GC, Puri P. BMC Pulm Med, Potential effect of household environment on prevalence of tuberculosis in India: Evidence from the recent round of a cross-sectional survey.,, 2018, 18,, 1672-,10.1186/s12890-018-0627-3 4. Mishra GP, Mulani JD. J Infect, First National Anti-Tuberculosis Drug Resistance Survey (NDRS) from India - An Eye Opener.,, 2018, 1,, 26-29, 5. Tiberi S, Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F. Lancet Infect Dis, Mfinanga. S.; Kapata, N.; Mwaba, P.; McHugh, T.D.; Ippolito, G.; Migliori, G.B.; Maeurer, M.J.; Zumla, A. Tuberculosis: Progress and advances in development of new drugs, treatment regimens, and host-directed therapies.,, 2018, 18,, e183-e198,
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|